PARPi triggers STING-dependent immune response and enhances therapeutic efficacy of immune checkpoint blockade independent of BRCAness
J. Shen, W. Zhao, Z. Ju, L. Wang, Y. Peng, M. Labrie, T. Yap, G. B. Mills, G. Peng
This study shows PARP inhibitors trigger an immune response via the STING pathway, enhancing immune checkpoint blockade efficacy regardless of BRCA mutations.
bioRxiv · May 10, 2018Cancer Biology